Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Adjusting for patient crossover in clinical trials using external data : a case study of lenalidomide for advanced multiple myeloma

Tools
- Tools
+ Tools

Ishak, K. Jack, Caro, J. Jaime, Drayson, Mark T., Dimopoulos, Meletios, Weber, Donna, Augustson, Bradley, Child, J. Anthony, Knight, Robert, Iqbal, Gulnaz, Dunn, Janet A., Shearer, Arran and Morgan, Gareth (2011) Adjusting for patient crossover in clinical trials using external data : a case study of lenalidomide for advanced multiple myeloma. Value in Health, Vol.14 (No.5). pp. 672-678. doi:10.1016/j.jval.2011.02.1182

Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1016/j.jval.2011.02.1182

Request Changes to record.

Abstract

Objectives
In some trials, particularly in oncology, patients whose disease progresses under the comparator treatment are crossed over into the experimental arm. This unplanned crossover can introduce bias in analyses because patients who crossover likely have a different prognosis than those who do not cross over; for instance, sicker patients not responding to standard therapy or those expected to benefit the most may be selectively chosen to receive the experimental treatment. Standard statistical methods cannot adequately correct for this bias. We describe an approach designed to minimize the impact of crossover, and illustrate this by using data from two randomized trials in multiple myeloma (MM).

Methods
The MM-009/010 trials compared lenalidomide and high-dose dexamethasone (Len+Dex) with dexamethasone alone (Dex). Nearly half (47%) of the patients randomized to Dex crossed over to Len with or without Dex (Len+/-Dex) at disease progression or study unblinding. Data from these trials was used to predict survival in an economic model evaluating the cost-effectiveness of lenalidomide. To adjust for crossover, the prediction equations were calibrated to match survival with Dex or Dex-equivalent therapies in trials conducted by the Medical Research Council (MRC) in the United Kingdom. To adjust for differences between the MM and MRC trial populations, a prediction equation was developed from the MRC data and used to predict survival by setting predictors to mean values for patients in the MM-009/010 trials. The expected survival with Dex without crossover was then predicted from the calibrated MM-009/010 equation (i.e., adjusted to match survival predicted from the MRC equation).

Results
The adjusted median overall survival predicted by the MRC equation was 19.5 months (95%CI, 16.6–22.9) for patients with one prior therapy, and 11.6 months (95% CI, 9.5–14.2) for patients with >1 prior therapy. These estimates are considerably shorter than was observed in the clinical trials: 33.6 months (27.1-NE) and 27.3 months (95% CI, 23.3–33.3) as of December 2005.

Conclusion
The calibration method described here is simple to implement, provided that suitable data are available; it can be implemented with other types of endpoints in any therapeutic area.

Item Type: Journal Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
Journal or Publication Title: Value in Health
Publisher: Wiley-Blackwell Publishing, Inc
ISSN: 1098-3015
Official Date: July 2011
Dates:
DateEvent
July 2011Published
Volume: Vol.14
Number: No.5
Page Range: pp. 672-678
DOI: 10.1016/j.jval.2011.02.1182
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item
twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us